| Biomarker | GDAP1 | Full name | Ganglioside Induced Differentiation-Associated Protein 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, risk stratification | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, siRNA validation) | ||
| Pathobiological Mechanisms | It contributes the most to overall survival, with high expression associated with poor prognosis. | ||||
| Clinical Availability Status | Research validation: Knockdown promotes apoptosis of THP-1 cells. | ||||
| Notes and Dynamics | One of the core prognostic factors in the line chart model. | ||||
| Biomarker | HSP90B2 | Full name | Heat shock protein 90 beta family member 2 | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Early screening, Risk stratification |
| Disease(or Constitution) | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | Involved in cell stress response, serum expression was up-regulated in CKD. | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | It is positively correlated with traditional markers such as serum creatinine and urea, and can be used as a supplementary detection index for renal injury. | ||||
| Biomarker | LOC541471 | Full name | Long Intergenic Non-Protein Coding RNA 541471 | Molecular Type | Nucleic acid (lncRNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, risk stratification | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, siRNA validation) | ||
| Pathobiological Mechanisms | High expression inhibits apoptosis and promotes proliferation, incorporated into the risk score model of the line graph | ||||
| Clinical Availability Status | Research Verification: TCGA Data + 52 clinical samples for validation. | ||||
| Notes and Dynamics | The risk stratification model constructed in combination with GDAP1, SOD1, and STK25 demonstrated high predictive accuracy. | ||||
| Biomarker | AAT | Full name | Alpha-1 antitrypsin | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Early screening, Risk stratification |
| Disease(or Constitution) | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | Inhibition of inflammation and apoptosis, abnormal serum levels after kidney injury | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | It can reduce renal ischemia-reperfusion injury and protect renal function by inhibiting inflammatory pathways. It is a potential protective biomarker for CKD. | ||||
| Biomarker | CRNDE | Full name | Colorectal Neoplasia Differentially Expressed | Molecular Type | Nucleic acid (lncRNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis and prediction of treatment response | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Blood/Bone marrow (real-time quantitative polymerase chain reaction, qRT-PCR) | ||
| Pathobiological Mechanisms | Downregulation of expression reduces the complete response rate, shortens the event-free survival (EFS) and overall survival (OS) | ||||
| Clinical Availability Status | Research verification: clinical data from 200 newly diagnosed AML patients supports. | ||||
| Notes and Dynamics | The prognostic value is more significant in cytogenetically normal AML and non-t(15;17) AML. | ||||
| Biomarker | AC | Full name | Acetylcarnitine | Molecular Type | Metabolites |
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Early screening, Risk stratification |
| Disease(or Constitution) | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | Participating in energy metabolism, abnormal levels reflect the imbalance of metabolic network in CKD patients. | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | It is related to the degree of renal function injury in CKD patients and can be used as an auxiliary evaluation index for CKD metabolic disorders. | ||||
| Biomarker | UNC93B1 | Full name | Unc-93 Homolog B1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (qRT-PCR, RNA sequencing) | ||
| Pathobiological Mechanisms | High expression of enriched innate immunity and metabolic pathways, negatively correlated with BCL2 leading to venetoclax resistance. | ||||
| Clinical Availability Status | Research validation: Multi-cohort validation (TCGA/GTEx/GEO), line graph concordance index 0.729. | ||||
| Notes and Dynamics | MCL-1 inhibitors can overcome the drug resistance mediated by MCL-1 and interact with hub genes such as S100A9. | ||||
| Biomarker | CSA | Full name | Cyclosporine A | Molecular Type | Metabolites |
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Early screening, Risk stratification |
| Disease(or Constitution) | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | Specific metabolites screened by omics reflect CKD metabolic disorders | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | The specific mechanism needs to be further clarified, and more studies are needed to verify its correlation with CKD progression and clinical value. | ||||
| Biomarker | IL1R1 | Full name | Interleukin 1 Receptor Type 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis and treatment benefit prediction | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | High expression is associated with monocyte differentiation and FLT3-ITD/RUNX1 mutations, increasing the risk of recurrence. | ||||
| Clinical Availability Status | Study validation: The Leucegene cohort (n=316) confirmed its value. | ||||
| Notes and Dynamics | Hematopoietic stem cell transplantation significantly improves 5-year overall survival in patients with high expression of intermediate-risk AML. | ||||
| Biomarker | 5-MTP | Full name | 5-Methoxytryptophan | Molecular Type | Metabolites |
| Molecular Formula | C₁₂H₁₄N₂O₃ | Molecular Weight | 234.25 g/mol | Core Functional Dimensions | Early screening, Risk stratification |
| Disease(or Constitution) | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | Regulating inflammation and fibrosis pathways, abnormal levels are associated with CKD progression | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | Inhibiting NF-κB pathway can improve CKD-induced cerebrovascular injury, which has the potential of biomarkers and therapeutic targets. | ||||
| Biomarker | TFRC | Full name | Transferrin Receptor 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, drug resistance-related | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Participates in iron metabolism, with abnormal expression affecting leukemia cell survival and chemotherapeutic response | ||||
| Clinical Availability Status | Research validation: As a prognostic marker, it works synergistically with DPP4. | ||||
| Notes and Dynamics | Upregulated in AML samples, its expression level can guide the selection of chemotherapy regimens. | ||||
| Biomarker | DPP4 | Full name | Dipeptidyl Peptidase 4 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, drug resistance-related | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Expression dysregulation affects chemotherapy sensitivity and participates in ferroptosis-related pathway regulation. | ||||
| Clinical Availability Status | Research validation: Incorporating the FRG prognostic model, the 1-5 year AUC value demonstrates predictive validity. | ||||
| Notes and Dynamics | Significantly downregulated in AML samples, closely associated with chemotherapy resistance. | ||||
| Biomarker | Creatine kinase | Full name | Creatine kinase | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | 86 kDa | Core Functional Dimensions | Diagnosis, Monitoring |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium, skeletal muscle, brain | Test Sample / Technology Platform | Serum (colorimetry, ELISA) | ||
| Pathobiological Mechanisms | Myocardial or skeletal muscle is released after injury, suggesting myocyte damage | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | Non-specific, contract enzyme detection is required | ||||
| Biomarker | PTBP1 | Full name | Polypyrimidine Tract Binding Protein 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, risk prediction | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (qRT-PCR, Western blot) | ||
| Pathobiological Mechanisms | Associated with internal tandem repeat mutations and complex karyotypes in FLT3, promoting cell proliferation and inhibiting apoptosis | ||||
| Clinical Availability Status | Research validation: The area under the curve (AUC) of 0.8601 can distinguish AML patients from the control group. | ||||
| Notes and Dynamics | Positively correlated with the proliferation marker Ki-67 and negatively correlated with the apoptosis marker p53, representing a potential drug target. | ||||
| Biomarker | NT-proBNP | Full name | N-terminal pro-brain natriuretic peptide | Molecular Type | Proteins |
| Molecular Formula | / | Molecular Weight | 10 kDa | Core Functional Dimensions | Prognosis, Monitoring |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Serum/Plasma (ELISA) | ||
| Pathobiological Mechanisms | BNP precursor fragment is more stable than BNP and reflects the state of cardiac function | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | It is more significant in severe myocarditis and its prognostic value is better than that of BNP | ||||
| Biomarker | ALOX5AP | Full name | Arachidonate 5-Lipoxygenase Activating Protein | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrowBlood, bone marrow | Test Sample / Technology Platform | Bone marrow (qRT-PCR, DNA methylation sequencing) | ||
| Pathobiological Mechanisms | Hypomethylation leads to overexpression, which is positively correlated with pro-leukemia genes and inhibits tumor-suppressive miRNAs. | ||||
| Clinical Availability Status | Study validation: Four independent cohorts (n=1186) confirm its prognostic value | ||||
| Notes and Dynamics | ROC curve demonstrates AML discrimination capability, with high expression indicating reduced overall survival | ||||